Your search history is turned on.
Date: April 8, 2024 Jurisdictions: British Columbia
Form 8-K for Marker Therapeutics INC filed 04/08/2024 Exhibit 99.1 Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies Preliminary data from study in patients with lymphoma enrolled at City of Hope National ...
Form 8-K for Marker Therapeutics INC filed 04/08/2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 8, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name ...
Date: March 26, 2024 Jurisdictions: British Columbia
Form 8-K for Marker Therapeutics INC filed 03/26/2024 Exhibit 99.1 Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following...
Form 8-K for Marker Therapeutics INC filed 03/26/2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name...
EDGAR PDF Exhibit 31.2 CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, Juan Vera, certify that: 1. I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make th...
EDGAR PDF Exhibit 31.1 CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, Juan Vera, certify that: 1. I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state...
EDGAR PDF Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tra...
Date: March 1, 2024 Jurisdictions: British Columbia
Form 8-K for Marker Therapeutics INC filed 03/01/2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 29, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact n...